6733 Stock Overview
Develops regenerative bio-orthopaedic products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioGend Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$36.60 |
| 52 Week High | NT$42.85 |
| 52 Week Low | NT$31.40 |
| Beta | 0.62 |
| 11 Month Change | -5.91% |
| 3 Month Change | -1.75% |
| 1 Year Change | 4.57% |
| 33 Year Change | 54.43% |
| 5 Year Change | 22.08% |
| Change since IPO | 10.57% |
Recent News & Updates
Shareholder Returns
| 6733 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.8% | 1.4% | 2.0% |
| 1Y | 4.6% | 1.3% | 31.8% |
Return vs Industry: 6733 exceeded the TW Biotechs industry which returned 1.3% over the past year.
Return vs Market: 6733 underperformed the TW Market which returned 31.8% over the past year.
Price Volatility
| 6733 volatility | |
|---|---|
| 6733 Average Weekly Movement | 2.3% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.1% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6733 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6733's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.biogend.com |
BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd. Fundamentals Summary
| 6733 fundamental statistics | |
|---|---|
| Market cap | NT$4.55b |
| Earnings (TTM) | -NT$109.93m |
| Revenue (TTM) | NT$156.64m |
29.0x
P/S Ratio-41.4x
P/E RatioIs 6733 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6733 income statement (TTM) | |
|---|---|
| Revenue | NT$156.64m |
| Cost of Revenue | NT$30.49m |
| Gross Profit | NT$126.16m |
| Other Expenses | NT$236.09m |
| Earnings | -NT$109.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 80.54% |
| Net Profit Margin | -70.18% |
| Debt/Equity Ratio | 0% |
How did 6733 perform over the long term?
See historical performance and comparison